Introduction
============

Epilepsy is a severe neurological disease affecting 65 million people worldwide ([@B33]). It is marked by abnormal electrical activity in the brain and is associated with precipitous recurrent episodes of involuntary movements and/or loss of consciousness. Various epilepsy syndromes have been described with different etiologies (e.g., genetic, structural, metabolic, infectious or unknown cause). In general, multiple genes and/or environmental factors are implicated in the pathogenesis of epilepsy but also monogenic epilepsy syndromes exist ([@B57]). Of interest, these monogenic pathologies can be mimicked rather easily by genetic animal models ([@B7]; [@B48]).

A *de novo* mutation in the *SCN1A* gene (sodium channel, voltage gated, type I alpha subunit) has been proven to be the cause in more than 85% of the DS patients ([@B24]). This monogenic epilepsy syndrome, which was also known as severe myoclonic epilepsy of infancy (SMEI), is an uncommon but severe encephalopathy that starts in the first year of life ([@B8]). Moreover it is one of the most drug-resistant epilepsy syndromes, highlighting the need for new innovative drugs with novel mechanisms of action.

Even though new AEDs have been developed over the past two decades, the treatment of drug-resistant epilepsy has not improved significantly ([@B52]). Notably, some interesting progress has been made in the understanding of the mechanisms underlying epilepsy, revealing novel targets for future AEDs ([@B22]). For instance, current evidence underscores the role of SER (5-HT) in epilepsy and it has been suggested that serotonergic drugs have great potential in the treatment of various epilepsy conditions ([@B14]).

One interesting example of a successful epilepsy therapy based on serotonergic modulation relates to the use of fenfluramine (FA) as an add-on drug in a small clinical trial of DS patients ([@B5]). FA is a potent SER releaser and also directly acts on multiple 5-HT receptor subtypes, 14 of which have been described in humans. Prospective data also demonstrated the efficacy and safety of FA in treating DS patients ([@B44]), which led to the initiation of clinical Phase III studies early in 2016^[1](#fn01){ref-type="fn"}^.

Zebrafish (*Danio rerio*) are increasingly used in neurological research ([@B2]) and the high genetic homology between ZF and human (ca. 70%) makes them an attractive model to study genetic diseases ([@B19]). More than 80% of the known epilepsy-related genes are found in the ZF genome and different groups were able to generate ZF epilepsy models by specific gene manipulation, recapitulating the main characteristics of the human disease, e.g., fever-sensitive myoclonic epilepsy (*CHD2* and *SCN1A*) ([@B49]; [@B60]) and fever-associated epilepsy (*STX1B*) ([@B45]). In addition, the phenotype of homozygous *scn1Lab* mutant ZF larvae (herein referred to as *scn1a* mutant larvae) has been studied and mirrors the clinical features of DS well. Significantly, these mutants did not respond to currently available AEDs and only valproic acid and FA were effective in treating seizures, as seen in DS patients ([@B7]; [@B48]).

Our pharmacological investigations using *scn1a* mutant larvae showed that stimulation of the 5-HT~2B~ receptor (by BW 723C86, a selective 5-HT~2B~-agonist) did not generate an anti-epileptiform effect whereas the application of selective 5-HT~1D~- (GR 46611), 5-HT~2A~- (TCB 2) or 5-HT~2C~- (lorcaserin) agonists resulted in a significant decrease of epileptiform locomotor and brain activity ([@B48]). However, direct evidence that these 5-HT receptor subtypes are implicated in the pharmacological activity of FA is presently lacking. Moreover, *in vitro* assays interrogating potential targets suggested beta~2~-adrenergic- (β~2~) and sigma- (σ) antagonism as possibly involved in the mechanism of FA ([@B38]). These receptors have relatively high protein similarity compared to their human counterparts, which amounts to 68.2 and 79.5 % for the β~2~ receptor and σ~1~ receptor, respectively \[as calculated by EMBOSS stretcher, ([@B40])\]. In addition, they show a pronounced expression in the ZF brain (comparable to the human proteins) ([@B54]; [@B32]). Structural data regarding the σ~2~ receptor subtype are more ill-defined, even though selective compounds with high affinity for the binding site are available ([@B39]).

In this study, the mechanistic profile of FA was explored in *scn1a* mutant larvae by using subtype selective agonists and antagonists of serotonergic, beta~2~-adrenergic- and sigma receptors. We demonstrate that the anti-epileptiform activity of FA originates both from its agonistic action at 5-HT~1D~ and 5-HT~2C~ receptors and its antagonistic action at σ~1~ receptors. Moreover, we found a significant decrease of certain monoamines in the head homogenates of ZF larvae after FA treatment. The results obtained allowed us to put forward a mechanistic hypothesis regarding the clinical efficacy of FA in the treatment of DS.

Materials and Methods {#s1}
=====================

Compounds and Their Maximum Tolerable Concentration (MTC)
---------------------------------------------------------

Compounds were purchased from Tocris Bioscience, except for the 5-HT~2A~-antagonist, ketanserin (Sigma-Aldrich) and (±)FA that was a gift from Prof. Berten Ceulemans (Child Neurology, University Hospital Antwerp, Belgium). Agonists and antagonists were selected by their high and selective affinity for a specific receptor (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**). In addition, all compounds have a cLogP value higher than one (cLogP \> 1.0) ensuring a good bioavailability in ZF larvae ([@B29]; [@B13]; [@B55]) (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**). These LogP values were calculated by an interactive calculator after conversion of the chemical names to SMILES (cLogP range between 1.21 and 4.59). Compounds were dissolved in DMSO (99.9% spectroscopy grade, Acros Organics) (stock solution), and immediately before use diluted in embryo medium to achieve a final DMSO concentration of 0.1% w/v that also served as VHC control.

###### 

Compounds with selective agonistic or antagonistic activity at the beta~2~-adrenergic (β~2~) or the sigma receptors (σ~1~ and σ~2~).

  Receptor          Full name    MTC (μM)   MW (g/mol)   cLogP   K~i~ (nM)   K~i~ (other receptor subtypes) (nM)   Reference
  ----------------- ------------ ---------- ------------ ------- ----------- ------------------------------------- -----------
  **AGONIST**                                                                                                      
  σ~1~-Agonist      PRE 084      6.25       317.43       3.63    2.2         13091.0 (σ~2~)                        [@B34]
  **ANTAGONIST**                                                                                                   
  β~2~-Antagonist   ICI 118551   50.00      277.41       2.93    1.2         120.0 (β1)                            [@B56]
                                                                             257.0 (β3)                            
  σ~1~-Antagonist   NE 100       6.25       327.47       4.35    1.0         212.0 (σ~2~)                          [@B34]
  σ~2~-Antagonist   SM 21        6.25       453.92       4.20    145.0       1050.0 (σ~1~)                         [@B26]

###### 

Compounds with selective agonistic or antagonistic activity at specific SER (5-HT) receptor subtypes.

  5-HT receptor subtype   Full name    MTC (μM)   MW (g/mol)   cLogP   K~i~ (nM)   K~i~ (other 5-HT receptor subtype) (nM)   Reference
  ----------------------- ------------ ---------- ------------ ------- ----------- ----------------------------------------- -----------
  **AGONIST**                                                                                                                
  1D-Agonist              PNU 109291   25.00      409.52       2.99    0.9         1700.0 (2A)                               [@B6]
                                                                                   1090.0 (1A)                               
  2A-Agonist              NBOH-2C-CN   1.25       312.37       2.96    1.3         132.0 (2C)                                [@B17]
  2C-Agonist              Ro 600175    1.25       226.68       1.21    1.0         31.6 (2A)                                 [@B51]
                                                                                   3981.1 (1A)                               
  **ANTAGONIST**                                                                                                             
  1D-Antagonist           LY 310762    2.50       435.44       4.44    249.0       --                                        [@B13]
  2A-Antagonist           Ketanserin   0.63       372.89       3.86    0.8         21.6 (2C)                                 [@B55]
                                                                                   28.7 (2A)                                 
  2B-Antagonist           SB 204741    6.25       467.78       4.59    1.0         100.0 (2B)                                [@B55]
                                                                                   158.0 (2A)                                
  2C-Antagonist           SB 242084    0.31       365.86       2.37    12.0        --                                        [@B55]

Before performing pharmacological experiments, the MTC of each compound was determined. Six dpf WT *scn1Lab*^+/+^ ZF larvae (hereinafter referred to as WT larvae) were incubated in a 96-well plate, one larva per well (tissue culture plate, flat bottom, FALCON^®^, USA), with different concentrations of compound or VHC at 28°C on a 14/10 h light/dark cycle (medium was replenished daily). Each larva was checked under the microscope during a period of 48 h for the following signs of toxicity: decreased or no touch response upon a light touch of the tail, loss of posture, body abnormalities, edema, anomalies in heart rate or circulation and death. The MTC was determined using 12 WT ZF larvae (6 dpf) and defined as the highest concentration at which none of these larvae showed signs of toxicity within 48 h of exposure. Compounds were used at their MTC (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**), whereas FA was used at a final concentration of 25 μM as described before ([@B48]).

Zebrafish Research
------------------

### Zebrafish Maintenance and Experimental Set-up

ZF (*Danio rerio*) heterozygous for the *scn1Lab* mutation (*scn1Lab*^+/-^), backcrossed with *Tupfel longfin* WT (WT *scn1Lab*^+/+^), were a generous gift of Dr. H. Baier (Freiburg, Germany). The adult ZF were kept at 28.0°C, on a 14/10 h light/dark cycle under standard aquaculture conditions. Fertilized eggs were collected via natural spawning. Genotyping of these ZF adults and embryos was performed as described previously ([@B48]). The embryos and larvae were kept in petridishes in embryo medium containing 1.5 mM HEPES, pH 7.6, 17.4 mM NaCl, 0.21 mM KCl, 0.12 mM MgSO~4~ and 0.18 mM Ca(NO~3~)~2~ in an incubator at 28.0°C, likewise on a 14/10 h light/dark cycle. *Scn1a* mutant larvae were selected by their darker appearance, lack of a swim bladder and slight curvature of the body ([@B43]).

All ZF experiments were approved by the Ethics Committee of the University of Leuven (Ethische Commissie van de KU Leuven, approval number 154/2015) and by the Belgian Federal Department of Public Health, Food Safety & Environment (Federale Overheidsdienst Volksgezondheid, Veiligheid van de Voedselketen en Leefmileu, approval number LA1210199).

### Locomotor Behavior

*Scn1a* mutant larvae and WT larvae were arrayed in a 96-well plate (one larva per well) and treated at 6 dpf with VHC, compound or co-treatment of compounds for a 22 h period as performed previously ([@B48]). The co-treatment of FA and subtype selective 5-HT-antagonists and/or the σ~1~-agonist was performed to investigate the mechanism of action of FA. After incubation at 28°C on a 14/10 h light/dark cycle and 30 min chamber habituation 7 dpf larvae were placed in an automated tracking device (ZebraBox^TM^ apparatus; Viewpoint, Lyon, France) and their locomotor behavior was evaluated during 10 min under dark conditions, as described before ([@B48]). Locomotor activity was quantified by the lardist parameter (total distance in large movements) and plotted in cm (ZebraLab^TM^ software, Viewpoint, Lyon, France). Data were collected and pooled together from two or three independent experiments with at least eight larvae per treatment condition. The locomotor data were analyzed by normalizing the locomotor activity of treated ZF larvae against age-matched VHC-treated larvae (method A), and by calculating the percentage of *scn1a* mutant larvae with epileptiform activity below or above a 70% threshold value using the cumulative locomotor activity during 10 min of each larva separately (method B). Method A has been described previously ([@B48]) and is performed for both *scn1a* mutant larvae and WT larvae. The threshold value used in method B is based on sensitivity analyses with different cut-off values in '10%-steps'; i.e., 10, 20, 30, 40, 50, 60, 70, 80, and 90% of the average cumulative locomotor activity during 10 min of VHC-treated *scn1a* mutant larvae per experiment (data available in Supplementary Tables [S1--S5](#SM1){ref-type="supplementary-material"}).

### Forebrain Local Field Potential Recordings

The epileptiform brain activity was measured by non-invasive surface recordings from the skin above the forebrain ([@B59]). *Scn1a* mutant and WT larvae were treated on 6 dpf as described above \[see Locomotor Behavior (Single and Combined)\] and recordings were performed at 7 dpf. ZF larvae were immobilized by 2% low-melting-point agarose (Invitrogen) (no paralytic was used).

The recording electrodes were made of borosilicate glass with microfilament (GC150TF-7.5, Harvard Apparatus, UK), pulled with DMZ Universal Puller (Zeitz, Germany) to an opening 15--20 microns, and filled with aCSF made from: 124 mM NaCl, 2 mM KCl, 2 mM MgSO~4~, 2 mM CaCl~2~, 1.25 mM KH~2~PO~4~, 26 mM NaHCO~3~ and 10 mM glucose. The differential signal was amplified 10,000 times using DAGAN 2400 amplifier (Minneapolis, MN, USA), band pass filtered at 0.3--300.0 Hz and digitized at 2.0 kHz via a PCI-6251 interface (National Instruments, UK) using WindEDR (John Dempster, University of Strathclyde, UK). Single recordings were performed for 10 min and epileptiform activity was quantified according to the duration of spiking paroxysms as described before ([@B48]). Electrograms were analyzed with Clampfit 10.2 software (Molecular devices corporation, USA). Spontaneous epileptiform activity was defined as events in which the amplitude exceeded three times the baseline and lasted longer than 50 ms. At least 10 (up to 50) ZF larvae were used per experimental condition.

### Neurotransmitter Determination

The heads of 7 dpf ZF larvae were used to quantify the amount of the neurotransmitters 5-HT, NAD, DOP, GABA and GLUT. Both *scn1a* mutant larvae and WT larvae were treated with either VHC or FA (*n* = 48 for both treatment arms, leading to a total of 192 larvae). Six heads per tube were homogenized and data acquisition was carried out as described before ([@B48]). Thereafter, the amount of neurotransmitter (in nmol) was determined and expressed as nmol neurotransmitter per mass head homogenate (mg).

Statistical Analysis
--------------------

GraphPad Prism 5 software (GraphPad Software, Inc.) was used for statistical analyses.

The locomotor activity was analyzed by the methods described above \[see Locomotor Behavior (Single and Combined)\]. The results obtained with method A were analyzed by One-way ANOVA and subsequent Dunnett's multiple comparison tests. The results obtained with method B were performed for the individual experiments by contingency tables, followed by Fisher's exact tests.

Electrographic brain activity was analyzed by a Student's *t*-test \[if data passed the normality test (D'Agostino & Pearson omnibus normality test)\]. Mann--Whitney *U* tests were used if the data did not pass the normality test, as described before ([@B48]). To determine if the genotype (*scn1a* mutant vs. WT) and/or FA treatment affected the neurotransmitter content, data were analyzed by a two-way ANOVA for genotype and FA treatment as the inter-subject factors. Regarding the analyses of single vs. triple experiments \[whether or not combined with FA; see Anti-epileptiform Activity Induced by Sigma~1~-Antagonism and 5-HT~1D&2C~-Agonism (Triple Treatment) and Counteraction of FA's Anti-epileptiform Activity by Sigma1-Agonism and 5-HT~1D&2C~-Agonism (Triple Treatment), respectively\] Mann--Whitney *U* tests were applied because the data did not pass the normality test.

For all analyses, differences between a treatment group and the equivalent control groups were considered statistically significant if the *p*-value was below 0.05 (*p* \< 0.05).

Results
=======

To explore the anti-epileptiform mechanism(s) of FA, we used an experimental workflow that is depicted in **Figure [1](#F1){ref-type="fig"}**.

![**Experimental workflow.** Selection of compounds based on hypothesized mechanisms of FA: stimulation (agonist, left side) or inhibition (antagonist, right side) of specific receptors. Light gray boxes show single treatment and dark gray boxes represent combinatorial treatment with FA.](fphar-08-00191-g001){#F1}

First, we selected compounds with specific agonistic or antagonistic activity at distinct receptor subtypes (i.e., 5-HT~1D~, 5-HT~2A~, 5-HT~2C~ receptors, and β~2~, σ~1~, σ~2~ receptors, respectively) and studied their effects on the locomotor and brain activity of *scn1a* mutant larvae.

The locomotor data were analyzed by normalizing the locomotor activity of treated ZF larvae against age-matched VHC-treated larvae (method A), and by calculating the percentage of *scn1a* mutant larvae with epileptiform activity below or above a 70% threshold value (method B). Method A was used to evaluate the results of both *scn1a* mutant larvae and WT larvae and has the advantage to demonstrate non-specific effects, e.g., a decrease in both mutant and WT larvae by sedative effects. Method B was applied to the data of the *scn1a* mutant larvae and has the advantage to account for the inherent variability of locomotor assays (i.e., different larvae at different days) since each larva is analyzed separately for each individual experiment.

In case of a significant decrease of epileptiform activity for a specific agonist/antagonist \[as shown by at least one method of locomotor analysis (A and/or B) and confirmed by forebrain LFP recordings\], we continued by treating larvae in separate experiments with a combination of FA and a compound (combinatorial treatment) with a counteractive profile of the agonist/antagonist previously used (in other words: in case of an active agonist, we combined FA with an antagonist and vice versa). Thereafter, we also tested the activity of the agonist/antagonist used in the combinatorial treatment as a single compound (control experiment). Finally, we performed triple treatment experiments to examine additional effects when combining all anti-epileptiform compounds. Similarly, we explored FA's pharmacological profile by combining FA with triple treatment of compounds with the counteractive profile of the agonists/antagonists previously used.

Anti-epileptiform Activity Induced by Sigma~1~-Antagonism, 5-HT~1D&2C~-Agonism
------------------------------------------------------------------------------

Blocking the β~2~-adrenergic receptor (by ICI 118551) or the σ~1~ receptor (by NE 100) resulted in a significant decrease of epileptiform locomotor activity of the *scn1a* mutant larvae, as identified by one of the two methods assessing locomotor activity (i.e., method A and method B, respectively) (**Figures [2A,B](#F2){ref-type="fig"}**). The β~2~-adrenergic receptor antagonist, however, also reduced the locomotor activity of WT larvae, whereas the σ~1~-antagonist did not (**Figure [2A1](#F2){ref-type="fig"}**). Subsequently, treated *scn1a* mutant larvae were subjected to brain activity recordings, showing that only the σ~1~-antagonist (NE 100) was able to significantly reduce epileptiform brain activity (**Figures [3A,B](#F3){ref-type="fig"}**). Representative traces of brain activity during 5 min recordings are depicted in **Figure [3C](#F3){ref-type="fig"}**. σ~2~-antagonism (by SM 21) did not decrease epileptiform locomotor or brain activity in *scn1a* mutant larvae but lowered the locomotor activity of WT larvae (**Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}**).

![**Activity profile of the selective beta~2~-antagonist (β~2~), sigma~1~-antagonist (σ~1~), sigma~2~-antagonist (σ~2~), subtype selective 5-HT-agonists (1D, 2A, 2C) and triple treatment with anti-epileptiform compounds \[σ~1~-antagonist and subtype selective 5-HT-agonists (1D and 2C)\] (locomotor behavioral assays).** Locomotor activity was normalized against VHC-treated *scn1a* mutant larvae and displayed as a percentage ± SD. **(A1)** Normalized locomotor activity of treated *scn1a* mutant larvae (-/-). **(A2)** Normalized locomotor activity of treated WT larvae (+/+). **(B)** Percentage of *scn1a* mutant larvae with epileptiform activity below (white area) or above the threshold value (black area). Treatment with the selective β~2~-antagonist, σ~1~-antagonist, the subtype selective 5-HT-agonists (1D, 2A, 2C) and triple treatment with anti-epileptiform compounds \[σ~1~-antagonist and subtype selective 5-HT-agonists (1D and 2C)\] induced anti-epileptiform locomotor activity. A statistical difference is indicated by: ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 and ^∗∗∗^*p* \< 0.001 vs. VHC-treated controls. *n* = 16--30 ZF larvae for all experimental conditions.](fphar-08-00191-g002){#F2}

![**Activity profile of the selective beta~2~-antagonist (β~2~), sigma~1~-antagonist (σ~1~), sigma~2~-antagonist (σ~2~), subtype selective 5-HT-agonists (1D, 2A, 2C) and triple treatment with anti-epileptiform compounds \[σ~1~-antagonist and subtype selective 5-HT-agonists (1D and 2C)\] (forebrain LFP recordings).** Quantification of brain recordings of VHC-treated WT larvae \[VHC(+/+), *n* = 42\], VHC-treated *scn1a* mutant larvae \[VHC(-/-), *n* = 41\] and compound-treated *scn1a* mutant larvae \[compound(-/-)\]. **(A)** Frequency of epileptiform events during 10 min recording. **(B)** Mean cumulative duration of epileptiform events during 10 min recording. Treatment with the selective β~2~-antagonist (*n* = 19) or the σ~2~-antagonist (*n* = 14) did not affect epileptiform brain activity in *scn1a* mutant larvae. In contrast, the σ~1~-antagonist (*n* = 20), 5-HT~1D~-agonist (*n* = 10), 5-HT~2A~-agonist (*n* = 10), the 5-HT~2C~-agonist (*n* = 14) and triple treatment with anti-epileptiform compounds \[σ~1~-antagonist and subtype selective 5-HT-agonists (1D and 2C); *n* = 11\] significantly reduced the frequency and the mean cumulative duration of epileptiform brain activity in *scn1a* mutant larvae. A statistical difference is indicated by: ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 and ^∗∗∗^*p* \< 0.001 vs. VHC-treated *scn1a* mutant larvae. **(C)** Visualization of representative electrograms of 7 dpf ZF larvae: VHC-treated WT larva \[VHC (+/+)\], VHC-treated *scn1a* mutant larva \[VHC (-/-)\]; β~2~-antagonist-treated *scn1a* mutant larva \[β~2~-antagonist (-/-)\]; triple treatment of *scn1a* mutant larva with anti-epileptiform compounds \[σ~1~-antagonist+5-HT~1D&2C~-agonists (-/-)\]; scale bars: 1 mV, 30 s.](fphar-08-00191-g003){#F3}

Previous work showed evidence for a role of 5-HT~1D~, 5-HT~2A~, and 5-HT~2C~ receptors in seizure modulation ([@B48]). Here we reconfirmed the anti-epileptiform effect of a distinct set of 5-HT-agonists (**Figures [2A,B](#F2){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Agonism at the 5-HT~1D~ (by PNU 109291) and 5-HT~2A~ receptor (by NBOH-2C-CN) also decreased epileptiform brain activity of *scn1a* mutant larvae (**Figures [3A,B](#F3){ref-type="fig"}**) and did not affect the locomotor activity of WT larvae (**Figure [2A1](#F2){ref-type="fig"}**). Similarly, the 5-HT~2C~-agonist (Ro 600175) decreased locomotor activity of *scn1a* mutant but also of the WT larvae (**Figure [2A1](#F2){ref-type="fig"}**). However, consecutive brain recordings proved the selective anti-epileptiform activity of this compound in *scn1a* mutant larvae (**Figures [3A,B](#F3){ref-type="fig"}**).

Anti-epileptiform Activity of FA and the Counteraction by Sigma~1~-Agonism or 5-HT~1D&2C~-Antagonism (Combinatorial Treatment)
------------------------------------------------------------------------------------------------------------------------------

In order to explore the mechanisms of action of FA, we combined FA with the σ~1~-agonist (PRE 084) or 5-HT subtype selective antagonists (**Figure [1](#F1){ref-type="fig"}** and **Table [2](#T2){ref-type="table"}**). First, we reconfirmed the anti-epileptiform activity of FA in both assays (locomotor and brain recordings) (**Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}**) as shown before ([@B7]; [@B48]). The σ~1~-agonist was unable to counteract the anti-epileptiform activity of FA in the locomotor assay (**Figures [4A,B](#F4){ref-type="fig"}**), although brain recordings revealed a statistically significant counteraction (**Figures [5A,B](#F5){ref-type="fig"}**). Treatment with the 5-HT~1D~-antagonist (LY 310762) or the 5-HT~2C~-antagonist (SB 242084) significantly counteracted the decrease in locomotor activity as elicited by FA in *scn1a* mutant larvae (**Figures [4A,B](#F4){ref-type="fig"}**). This was not the case for the 5-HT~2A~-antagonist (ketanserin). The locomotor behavior was not significantly altered in age-matched WT larvae by combinatorial treatments (**Figure [4A2](#F4){ref-type="fig"}**), pointing to a selective effect on *scn1a* mutant larvae. Interestingly, quantification of the corresponding electrograms confirmed the significant counteraction of the 5-HT~1D~-antagonist and 5-HT~2C~-antagonist (**Figures [5A,B](#F5){ref-type="fig"}**). Representative traces of brain activity during 5 min recording are depicted in **Figure [5C](#F5){ref-type="fig"}**. Finally, we performed experiments with a selective 5-HT~2B~-antagonist (SB 204741, negative control). This antagonist was unable to counteract the anti-epileptiform activity of FA in the locomotor (**Figures [4A,B](#F4){ref-type="fig"}**) and the brain recording assays (**Figures [5A,B](#F5){ref-type="fig"}**).

![**Activity profile of FA \[single treatment with FA and combinatorial treatment of FA with the sigma~1~-agonist (σ~1~) or subtype selective 5-HT-antagonists (1D, 2A, 2C, 2B) or triple treatment of epileptiform compounds \[σ~1~-agonist and subtype selective 5-HT-antagonists (1D and 2C)\] (locomotor behavioral assays)\].** Locomotor activity was normalized against VHC-treated *scn1a* mutant larvae (-/-) and displayed as a percentage ± SD. **(A1)** Normalized locomotor activity of treated *scn1a* mutant larvae (-/-). **(A2)** Normalized locomotor activity of treated WT larvae (+/+). **(B)** Percentage of *scn1a* mutant larvae with epileptiform activity below (white area) or above the threshold value (black area). Single treatment with FA induced anti-epileptiform locomotor activity (FA), which was counteracted by combinatorial treatment with the 5-HT~1D~-antagonist or the 5-HT~2C~-antagonist or triple treatment of epileptiform compounds \[σ~1~-agonist and subtype selective 5-HT-antagonists (1D and 2C)\]. A statistical difference is indicated by: ^∗^*p* \< 0.05 and ^∗∗∗^*p* \< 0.001 vs. VHC-treated controls (or FA-treated larvae). *n* = 16--30 ZF larvae for all experimental conditions.](fphar-08-00191-g004){#F4}

![**Activity profile of FA \[single treatment with FA and combinatorial treatment of FA with the sigma~1~-agonist (σ~1~) or subtype selective 5-HT-antagonists (1D, 2A, 2C, 2B) or triple treatment of epileptiform compounds \[σ~1~-agonist and subtype selective 5-HT-antagonists (1D and 2C)\] (forebrain LFP recordings)\].** Quantification of brain recordings of VHC-treated WT larvae \[VHC(+/+), *n* = 42\], VHC-treated *scn1a* mutant larvae \[VHC(-/-), *n* = 41\] and compound-treated *scn1a* mutant larvae \[compound(-/-)\]. **(A)** Frequency of epileptiform events during 10 minutes recording. **(B)** Mean cumulative duration of epileptiform events during 10 min recording. Single treatment with FA reduced epileptiform brain activity (*n* = 50), which was counteracted by combinatorial treatment with the σ~1~-agonist (*n* = 13), the 5-HT~1D~-antagonist (*n* = 18) or the 5-HT~2C~-antagonist (*n* = 16). A statistical difference is indicated by ^∗^*p* \< 0.05 and ^∗∗∗^*p* \< 0.001. **(C)** Visualization of representative electrograms of 7 dpf ZF larvae: FA-treated *scn1a* mutant larva \[FA(-/-)\]; FA-treated *scn1a* mutant larva in combination with the σ~1~-agonist \[FA+ σ~1~-agonist(-/-)\] or triple treatment with epileptiform compounds \[σ~1~-agonist+5-HT~1D&2C~-antagonists (-/-)\]; scale bars: 1 mV, 30 s.](fphar-08-00191-g005){#F5}

No Anti-epileptiform Activity of Sigma~1~-Agonism or 5-HT-Antagonism
--------------------------------------------------------------------

Subsequently, we performed single treatment experiments to investigate whether the compounds, used in combinatorial treatment with FA \[see Anti-epileptiform Activity of FA and the Counteraction by Sigma~1~-Agonism or 5-HT~1D&2C~-Antagonism (Combinatorial Treatment)\], affected the locomotor activity of ZF larvae in the absence of FA (**Figure [6](#F6){ref-type="fig"}**). Treatment with the σ~1~-agonist did not significantly influence the locomotor activity of ZF larvae, although a slight statistically insignificant increase in the epileptiform behavior of *scn1a* mutant larvae was present (*p* \> 0.05, **Figure [6A](#F6){ref-type="fig"}**). The pharmacological inhibition of the 5-HT~1D~, 5-HT~2A~, and the 5-HT~2C~ receptor did not alter epileptiform locomotor activity in *scn1a* mutant larvae (**Figures [6A,B](#F6){ref-type="fig"}**). The 5-HT~1D~-antagonist and the 5-HT~2B~-antagonist significantly affected locomotor activity of age-matched WT larvae (**Figure [6A1](#F6){ref-type="fig"}**).

![**Activity profile of the sigma~1~-agonist (σ~1~) and subtype selective 5-HT-antagonists (1D, 2A, 2C, 2B) (locomotor behavioral assays).** Locomotor activity was normalized against VHC-treated *scn1a* mutant larvae (-/-) and displayed as a percentage ± SD. **(A1)** Normalized locomotor activity of treated *scn1a* mutant larvae (-/-). **(A2)** Normalized locomotor activity of treated WT larvae (+/+). **(B)** Percentage of *scn1a* mutant larvae with epileptiform activity below (white area) or above the threshold value (black area). Single treatment with the σ~1~-agonist (σ~1~) and the subtype selective 5-HT-antagonists (1D, 2A, 2C, 2B) did not significantly affect the epileptiform locomotor behavior. A statistical difference is indicated by: ^∗^*p* \< 0.05 vs. VHC-treated controls. *n* = 20 ZF larvae for all experimental conditions.](fphar-08-00191-g006){#F6}

Anti-epileptiform Activity Induced by Sigma~1~-Antagonism and 5-HT~1D&2C~-Agonism (Triple Treatment)
----------------------------------------------------------------------------------------------------

Single treatment (σ~1~-antagonist, 5-HT~1D~- or 5-HT~2C~-agonist) decreased the abnormal (epileptiform) locomotor activity (range 17--34% decrease compared to VHC; **Figure [2A1](#F2){ref-type="fig"}**). Triple treatment (combination of the aforementioned three compounds) decreased the epileptiform locomotor activity to a greater extent (58% decrease compared to VHC, **Figure [2A1](#F2){ref-type="fig"}**), which is similar to the decrease elicited by FA (\>55% decrease compared to VHC; **Figure [4A1](#F4){ref-type="fig"}**). Subsequent brain recordings confirmed these anti-epileptiform effects, though no major differences were observed between single and triple treatment (**Figures [3](#F3){ref-type="fig"}, [5](#F5){ref-type="fig"}**). Consistently, statistical analyses did not show any significant differences between triple treatment and single treatments (*p* \< 0.05).

Counteraction of FA's Anti-epileptiform Activity by Sigma~1~-Agonism and 5-HT~1D&2C~-Antagonism (Triple Treatment)
------------------------------------------------------------------------------------------------------------------

Combinatorial treatment of FA with single treatment of the σ~1~-agonist, 5-HT~1D~- or 5-HT~2C~-antagonist counteracted FA's decrease in locomotor activity (range 0--41% increase relative to FA; **Figure [4A1](#F4){ref-type="fig"}**). Triple treatment (combination of the aforementioned three compounds) counteracted FA's decrease in locomotor activity more profoundly (89% increase relative to FA; **Figure [4A1](#F4){ref-type="fig"}**). Consistently, brain recordings confirmed the counteraction of FA's anti-epileptiform effect and showed that triple treatment counteracted FA's effect more profoundly (116--144% increase relative to FA for the frequency and cumulative duration of epileptiform events, respectively; **Figure [5](#F5){ref-type="fig"}**), in comparison to the single treatment counteraction experiments (74--91% relative to FA for the frequency and cumulative duration of epileptiform events, respectively; **Figure [5](#F5){ref-type="fig"}**). Overall, these more pronounced counteractive effects by triple treatment compared to single treatments were not statistically significant (*p* \> 0.05).

Neurotransmitter Changes after FA Treatment
-------------------------------------------

Our data indicate an overall reduction of two out of three monoamines after FA treatment, i.e., DOP and NAD (**Figure [7](#F7){ref-type="fig"}**). The most pronounced and significant decrease was shown for NAD (**Figure [7](#F7){ref-type="fig"}** and Supplementary Table [S6](#SM1){ref-type="supplementary-material"}).

![**Neurotransmitter content in head homogenates of ZF larvae (nmol/mg).** Data for each condition were collected from eight samples with each six heads (*n* = 48). ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 indicate a statistically significant alteration of some neurotransmitters (Supplementary Table [S6](#SM1){ref-type="supplementary-material"}; Two-way ANOVA).](fphar-08-00191-g007){#F7}

The only statistical significant difference between both genotypes was the GLUT content which was significantly higher in *scn1a* mutant larvae (-/-) when compared to WT larvae (+/+). However, GLUT content was not significantly altered after FA treatment (**Figure [7](#F7){ref-type="fig"}** and Supplementary Table [S6](#SM1){ref-type="supplementary-material"}).

Discussion
==========

Dravet syndrome is one of the most drug-resistant forms of epilepsy that typically starts in the first year of life ([@B36]). Recently, it was shown that the serotonergic drug FA is a potent add-on AED in DS patients ([@B5]). Although this compound shows great promise for future therapeutic regimens in the treatment of DS and possibly other drug-resistant epileptic syndromes, it is presently unknown which 5-HT receptor subtypes are involved in its action and whether other mechanisms beyond its serotonergic profile play a part. This situation hampered a full mechanistic appreciation of the clinical performance of the compound.

Serotonergic Activity (5-HT)
----------------------------

In previous experimental work using *scn1a* mutant larvae, which mimic well the epileptiform features of DS in ZF, we have shown that selective pharmacological agonists of the 5-HT~1D~, 5-HT~2A~ and 5-HT~2C~ receptor subtypes (GR 46611, TCB 2 and lorcaserin, respectively) substantially decreased the epileptiform activity. Of importance, stimulation of other 5-HT receptor subtypes was not met with success. Using an identical approach here, we explored whether selective antagonists of 5-HT~1D~, 5-HT~2A~ and 5-HT~2C~ receptor subtypes were able to counteract the FA-induced inhibition of epileptiform locomotor and brain activity observed in *scn1a* mutant larvae. We show that antagonists of 5-HT~1D~ and the 5-HT~2C~ receptor subtypes were able to do so (LY 310762 and SB 242084, respectively), but notably, the 5-HT~2A~-antagonist (ketanserin) was not.

Of importance, and in line with our previous findings ([@B48]), a 5-HT~2B~-antagonist (SB 204741) did not counteract the anti-epileptiform activity of FA. Consequently, we can conclude that the 5-HT~2B~ receptor subtype, that is proven to cause cardiotoxic effects after prolonged use of FA ([@B41]), is not involved in the anti-epileptiform effect of FA.

We also examined the anti-epileptiform activity of the subtype selective 5-HT~1D~-, 5-HT~2A~- and 5-HT~2C~-antagonists without combinatorial FA treatment (i.e., single treatment) as other studies have shown that blocking these receptor subtypes can protect against seizures in other seizure/epilepsy models. For example, the 5-HT~2A~-antagonist used in this study, ketanserin, protected against seizures induced by hippocampal kindling in cats ([@B53]). The same antagonist was also involved in increasing the latency to audiogenic seizures in DBA/2 mice ([@B46]). Consistently, the 5-HT~2C~-antagonist, mesulergine, inhibited myoclonic jerks induced by 5-HTP in guinea pigs. This latter antagonist primarily blocks the 5-HT~2C~ receptor and displays affinity for the 5-HT~2A~ receptor subtype ([@B37]). Selective pharmacological blockade of the 5-HT~1D~ receptor also inhibited myoclonic jerks in the same model of generalized myoclonus ([@B16]). However, our data clearly show that antagonists for these 5-HT receptor subtypes did not show any anti-epileptiform activity in our ZF model of DS.

Beta~2~-Adrenergic Activity (β~2~)
----------------------------------

The activity of FA has always been labeled as 5-HT related, as confirmed in this study. Nonetheless, recent *in vitro* data suggested antagonism of sigma (σ) and beta~2~-adrenergic (β~2~) receptors as part of its pharmacological spectrum ([@B38]). Hence, in this study we used the *scn1a* mutant larvae to explore the anti-epileptiform activity of σ- and β~2~- antagonism in *in vivo* conditions.

A selective antagonist of the β~2~-adrenergic receptor (ICI 118551) was able to significantly reduce the locomotor activity of *scn1a* mutant larvae. This is in agreement with the findings of [@B23], that showed an anti-epileptiform effect against maximal electroshock-induced seizures in mice by antagonizing the β-adrenergic receptor. Additionally, β-adrenergic receptors have been implicated in audiogenic seizures and pindolol, a potent β-antagonist, was found to attenuate audiogenic seizures in DBA/2 mice ([@B21]). Nevertheless, in this work we show that the percentage of *scn1a* mutant larvae with decreased epileptiform activity was not significantly changed. In addition, the locomotor activity of WT larvae was decreased, suggesting a non-specific alteration of locomotor activity (i.e., potential sedative or muscle-relaxant effect). In line with these latter findings, the β~2~-antagonist did not decrease epileptiform brain activity. Thus, our *in vivo* data imply that the β~2~-adrenergic receptor is not involved in modulating epileptiform activity in the ZF DS model.

Sigma Activity (σ~1~ and σ~2~)
------------------------------

As far as the sigma receptors are concerned, the σ~1~-antagonist (NE 100) decreased both epileptiform behavior and especially brain activity in *scn1a* mutant larvae. On the other hand, the σ~1~-agonist (PRE 084) did not counteract FA's decrease in abnormal locomotor activity (behavioral assays, **Figure [4](#F4){ref-type="fig"}**), whereas brain activity recordings clearly demonstrated a statistically significant counteraction (**Figure [5](#F5){ref-type="fig"}**). Locomotion is regulated in a complex way in different parts of the brain ([@B9]) and it is possible that these neuronal activities are not always consistent with the brain activity alterations recorded by a single electrode positioned at the forebrain. Alternatively, it is also conceivable that the σ~1~-agonist (PRE 084) does not uniformly distribute over the brain, and that especially the peripheral areas probed by the electrode accumulated more compound resulting in a more pronounced effect.

Altogether, the data therefore suggest an involvement of the σ~1~ receptor in the mechanism of FA, beyond its serotonergic profile. In contrast, treatment with the σ~2~-antagonist (SM 21) did not reduce epileptiform activity in *scn1a* mutant larvae. This result was somewhat anticipated as most studies underline the role of the σ~2~ subtype receptor in cancer-related diseases, rather than in brain-related disorders ([@B42]).

Of interest, a number of studies demonstrate the role of σ~1~ receptors in neurological diseases like epilepsy ([@B42]) and overstimulation of σ~1~ receptors has been associated with GLUT-related excitatory effects (via NMDA receptors) ([@B3]; [@B35]; [@B42]). In addition, blockade of σ~1~ receptors was associated directly with anti-epileptiform activity ([@B25]). In contrast, also σ~1~-agonists have also been shown to exert clear anti-seizure effects ([@B28]; [@B15]), and possibly σ~1~-agonist/antagonists might exert different activities depending on the seizure/epilepsy model. Anyhow, our data show that σ~1~-agonism was ineffective in reducing epileptiform events, whereas σ~1~-antagonism likely plays a role in the mechanism of FA in the ZF DS model.

Neurotransmitter Content
------------------------

The neurotransmitter content analysis of *scn1a* mutants compared to WT only demonstrated a statistically significant increase in GLUT (*p* = 0.0036). This finding is in line with the neuro-excitatory properties related to GLUT and its role in epilepsy ([@B27]). Hence it is not surprising that decreasing glutamatergic effects is one of the main targets for currently available AEDs ([@B20]). Nonetheless, the anti-epileptic compound FA did not alter GLUT levels. Interestingly, the concentration of other neurotransmitters (i.e., NAD and DOP) in head homogenates was altered after FA treatment. Our data indicate a significant DOP decrease by almost one third compared to the VHC treated group (*p* = 0.0335). The NAD content was even nearly halved when comparing the FA vs. the VHC treated group (*p* = 0.0035). The latter result is therefore in line with previous work that demonstrated a FA-related decrease of the NAD content in rat brain ([@B4]).

As 5-HT-agonism ([@B1]) but also σ-antagonism ([@B31]) can result in decreased NAD signaling, we hypothesize that the reduction of NAD content after FA treatment as observed in this study is due the effects of FA at 5-HT~2C~ and σ~1~ receptors. Of interest, elevated NAD transmission has been associated with some cases of epilepsy ([@B11]) and although some studies show contradictory results ([@B50]), also evidence exists supporting the use of NAD-decreasing drugs in the treatment of neurological diseases, including epilepsy ([@B12]).

Of importance, the concentrations measured encompass the total intra- and extracellular levels, so inter-synaptic level alterations were not assessed.

The following, yet incomplete, hypothesis emerges regarding the pharmacological profile of FA that underlies the treatment of DS and possibly other *SCN1A*-related epilepsies. Of importance, the present study used only one agonist or antagonist at their respective MTCs for the exploration of the involvement of some type of receptors, and further experiments using alternative methods (e.g., a genetic approach using receptor gene knock-down or overexpression) are needed to confirm the present results.

*SCN1A* mutations, as a major monogenic cause of DS, lead to a malfunction of the encoded voltage-gated sodium channels 1.1 (Na~v~1.1). In mammalian (rodent) DS models these channels are mainly affected in inhibitory (GABAergic) interneurons and to a lesser extent in excitatory pyramidal neurons ([@B10]; [@B30]). As a result, neuronal inhibition is impaired, which is assumed to cause seizures ([@B58]). Our data suggest that FA reduces epileptiform activity by stimulating 5-HT~2C~ and 5-HT~1D~ receptors, leading to enhanced GABAergic neurotransmission (as proven for 5-HT~2C~ receptors) ([@B47]; [@B18]), and by a σ~1~-antagonistic action that can reduce the excitatory neurotransmission by modulating NMDA responses ([@B42]). In addition, FA also significantly decreases the NAD brain content that might contribute to its anti-epileptic effects.

Conclusion
==========

This work extends our current understanding of the anti-epileptic mechanisms of FA, beyond its serotonergic activity. Using an *in vivo scn1a* mutant ZF model we demonstrated that the anti-epileptiform activity of FA not only originates from its 5-HT~1D~- and 5-HT~2C~-agonism, but likely also from its ability to block σ~1~ receptors. These findings will help to understand the pharmacological profile of compounds that is critical for their applicability in the treatment of DS and possibly also other drug-resistant epilepsies.
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5-HT

:   5-hydroxytryptamine (serotonin)

5-HTP

:   5-Hydroxy tryptophan

aCSF

:   artificial cerebrospinal fluid

AED

:   anti-epileptic drug

cLogP

:   calculated LogP

DMSO

:   dimethylsulfoxide

DOP

:   dopamine

dpf

:   days post fertilization

DS

:   Dravet syndrome

EEG

:   electroencephalogram

GABA

:   γ-aminobutyric acid

GLUT

:   glutamate

lardist

:   distance in large movements (cm)

LFP

:   local field potential

ms

:   milliseconds

MTC

:   maximum tolerable concentration

mV

:   millivolt

NAD

:   noradrenaline

Na~v~1.1

:   sodium channel protein type 1 subunit alpha isoform 1

Na~v~1.5

:   sodium channel protein type 1 subunit alpha isoform 5

NMDA

:   *N*-methyl-[D]{.smallcaps}-aspartate

*SCN1A*

:   sodium channel, voltage gated, type I alpha subunit (human)

*scn1Lab*

:   sodium channel, voltage-gated, type I like, alpha b (zebrafish)

SER

:   serotonin

VHC

:   vehicle

WT

:   wild type

ZF

:   zebrafish
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